Diabetes mellitus ve komplikasyonlarının tanı,tedavi ve izlem ...

41. Ganda O, Beaser R, Blair E, et al. Joslin Diabetes Center & Joslin Clinic Clinical guideline for
pharmacological management of type 2 diabetes. 2009;1-9.
42. Gill G (Editor). Unstable and Brittle Diabetes. Taylor & Francis, London,2004.
43. Goldstein BJ, Müler-Wieland D (Editors). Textbook of Type 2 Diabetes. Martin Dunitz, London, 2003.
44. Heymann AD, Shapiro Y, Chodick G, et al. Reduced hospitalizations and death associated with influenza
vaccination among patients with and without diabetes. Diabetes Care 2004;27:2581-4.
45. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin
A1C in human blood and the national standardization schemes in the United States, Japan, and
Sweden: a method-comparison study. Clin Chem 2004;50:166–74.
46. Holman R, Paul S, Bethel M, et al. Long-term follow-up after tight control of blood pressure in type
2 diabetes. N Engl J Med 2008;359:1565-76.
47. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evalunted for candiovascular outcomes
in oral agent combination therapyfortype 2 diabetes (RECORD); a multicentre, randomized, openlabel
trial. Zancet 2009; Jun 20;373(9681):2125-35.
48. Huang E, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected
benefits of intensive glucose in older patients with type 2 diabetes: a decision analysis. Ann Intern
Med 2008;149:11-9.
49. IDSA & IWGDF guidelines for clinicians diagnosing diabetic foot infections. Clinical Infectious Diseases.
October 1, 2004.
50. International Diabetes Federation. Diabetes Atlas 3rd Edition, Brussels, IDF Publ., 2006.
51. International Diabetes Federation. IDF Clinical Guidelines Taskforce. Global Guideline for Type 2
Diabetes. IDF Publ., Brussels, 2005.
52. Inzucchi SE, Porte DJr, Sherwin RS, Baron A (Editors). The Diabetes Manual: A Primary Care Companion
to Ellenberg and Rifkin’s. Sixth Edition. McGraw-Hill Medical Publishing Division, NewYork, 2005.
53. Jameson JL, Kasper DL, Fauci AS, et al (Editors). Harrison’s Endocrinology. Sixteenth Edition, McGraw-
Hill, New York, 2006.
54. Kahn RC, Weir GC, King GL, et al (Editors). Joslin’s Diabetes Mellitus. Fourteenth Edition. Boston,
Lippincott Williams & Wilkins, 2005.
55. Katz P, Gilbert J. Diabetes and cardiovascular disease among older adults: an update on the evidence.
Geriatr Aging 2008;11:509-14.
56. Kaufman F, Halvorson MJ, Lohry J (Editors). Putting Your Patients on the Pump. Fast Fact Series,
ADA Publications, Alexandria, 2001.
57. Lachin JM, Genuth S, Nathan DM, et al, and DCCT/EDIC Research Group. Effect of glycemic exposure
on the risk of microvascular complications in the diabetes control and complications trial--revisited.
Diabetes. 2008;57:995-1001.
58. Leibovitz H (Editor). Management of Type 2 Diabetes and its Related Disorders. Fourth Edition, ADA
Publ, Alexandria, 2004.
59. Leyden R, Standl E, Bartnik M, et al. ESC/EASD Guidelines on pre-diabetes, diabetes and cardiovascular
diseases: Executive summary. European Heart Journal 2007;28:88-136.
60. Little RR, England JD, Wiedemeyer HM, et al. Glycated haemoglobin predicts progression to diabetes
mellitus in Pima Indians with impaired glucose tolerance. Diabetologia 1994;37:252–6.
61. Little RR, Rohlfing CL, Tennill AL, et al. Effects of sample storage conditions on glycated hemoglobin
measurement: evaluation of five different high performance liquid chromatography methods. Diabetes
Technol Ther 2007;9:36–42.
62. Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program:
a five year progress report. Clin Chem 2001;47:1985–92.
63. Matthaei S, Bierwirth R, Fritsche A, et al. Medikamentöse antihyperglykämische therapie des diabetes
mellitus typ 2: Update der evidenzbasierten leitlinie der DDG. 2008. (http://www.deutschediabetesgesellschaft.de)
DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU | 173